MET097 matching placebo
Sponsors
Metsera Inc.
Conditions
Obesity
Phase 3
EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY-
BIASED ULTRA LONG-ACTING GLP-1RA IN PEOPLE WITH
OVERWEIGHT OR OBESITY: A PHASE 3, MULTI-CENTER
RANDOMIZED, CONTROLLED TRIAL (VESPER-4)
Not yet recruitingCTIS2025-523974-18-00
Target: 135Updated: 2026-04-03
EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY-
BIASED ULTRA LONG-ACTING GLP-1 RA IN PEOPLE WITH
OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3,
MULTI-CENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL
(VESPER-5)
Not yet recruitingCTIS2025-523975-48-00
Target: 335Updated: 2026-04-16